Login    Join free Add to favorites    中文
Home >Products> Reagents >Biochemistry> Sunitinib Malate
Sunitinib Malate
Origin of place United States
Model 341031-54-7
Supplier BOC Sciences
Price $398
Hits 139
Updated 2/10/2023
  • Product Detail
  • Company Profile
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.https://www.bocsci.com/product/sunitinib-malate-cas-341031-54-7-187069.html
bio-equip.cn
Request Infomation

* Name:
Title:
* Tel:
Fax:
* E-mail:
Postcode:
Institution/Company:
Address:
* Country:
Request infomation:
yes no
Request Quotation:
yes no
* Message:
Validated Code:
refresh
I agree to share my inquiry to the other matching suppliers.



Recently viewed products
Copyright(C) 2006-2025 Bio-Equip    E-mail:web@bio-equip.cn   沪ICP备06040519号